{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:26:17Z","timestamp":1751300777275},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12032-018-1189-1","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T07:23:32Z","timestamp":1533367412000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1007","volume":"35","author":[{"given":"Sally C.","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"key":"1189_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol"},{"key":"1189_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB. IIIrd, et al: Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13:78\u2013108.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000353785","volume":"98","author":"H Jann","year":"2013","unstructured":"Jann H, Denecke T, Koch M, et al. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2013;98:137\u201343.","journal-title":"Neuroendocrinology"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","volume":"33","author":"PL Kunz","year":"2015","unstructured":"Kunz PL. Carcinoid and neuroendocrine tumors: building on success. JCO. 2015;33:1855\u201363.","journal-title":"JCO"},{"key":"1189_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1023\/A:1008383132024","volume":"11","author":"S Ricci","year":"2000","unstructured":"Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127\u201330.","journal-title":"Ann Oncol"},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656\u201363.","journal-title":"J Clin Oncol"},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333.","journal-title":"N Engl J Med"},{"key":"1189_CR8","first-page":"289","volume":"4","author":"SH Rosenoff","year":"2006","unstructured":"Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol. 2006;4:289\u201394.","journal-title":"J Support Oncol"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","volume":"40","author":"L Anthony","year":"2011","unstructured":"Anthony L, Vinik AI. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas. 2011;40:987\u201394.","journal-title":"Pancreas"},{"key":"1189_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000082875","volume":"80","author":"P Ruszniewski","year":"2004","unstructured":"Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80:244\u201351.","journal-title":"Neuroendocrinology"},{"key":"1189_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12325-011-0062-9","volume":"28","author":"WH Ludlam","year":"2011","unstructured":"Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011;28:825.","journal-title":"Adv Ther"},{"key":"1189_CR12","first-page":"4127","volume":"29","author":"MK Chadha","year":"2009","unstructured":"Chadha MK, Lombardo J, Mashtare T, et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009;29:4127\u201330.","journal-title":"Anticancer Res"},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","volume":"21","author":"MS Broder","year":"2015","unstructured":"Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21:1945\u201355.","journal-title":"World J Gastroenterol"},{"key":"1189_CR14","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"EM Wolin","year":"2015","unstructured":"Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Dev Ther. 2015;9:5075\u201386.","journal-title":"Drug Des Dev Ther"},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"1189_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul J, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313.","journal-title":"N Engl J Med"},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525\u201334.","journal-title":"Lancet Oncol"},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1634\/theoncologist.2015-0381","volume":"21","author":"C Shen","year":"2016","unstructured":"Shen C, Xu Y, Dasari A, et al. Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. Oncologist. 2016;21:308\u201313.","journal-title":"Oncologist"},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/cam4.435","volume":"4","author":"K Al-Efraij","year":"2015","unstructured":"Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015;4:864\u201370.","journal-title":"Cancer Med"},{"key":"1189_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930\u20136.","journal-title":"Oncologist"},{"key":"1189_CR21","first-page":"326","volume":"35","author":"P Ferolla","year":"2012","unstructured":"Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest. 2012;35:326\u201331.","journal-title":"J Endocrinol Invest"},{"key":"1189_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1189-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1189-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T23:19:37Z","timestamp":1564874377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1189-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1189-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Specifically, the Health Research Ethics Board (HREB) approved this study before its conduct.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Because this study was a secondary analysis of retrospective data, there was no direct contact with any participants. Therefore, informed consent was waived by the ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"123"}}